MANNHEIM, Germany, Aug. 29, 2024 — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company focused on restoring patients’ natural ability to fight cancer, announced today that it will release second quarter 2024 financial results and a corporate update on Thursday, September 5, 2024. The Company will hold a conference call at 8:30 a.m. EDT / 14:30 CET.

The conference call will be accessible via phone and webcast. The live audio webcast of the call will be available on the “Webcasts” section under the “Investors” page of the Affimed website at . To access the call by phone, please use link
, where you will be provided with dial-in details and a pin number.

Note: To avoid delays, participants are advised to dial into the conference call 15 minutes before the scheduled start time. A replay of the webcast will be available at the same link for 30 days following the call.

About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company dedicated to empowering patients to fight cancer by leveraging the full potential of the innate immune system. The Company’s innate cell engagers (ICE^®) enable a targeted approach to identify and destroy a variety of hematologic and solid tumors. ICE^® are developed using the Company’s proprietary ROCK^® platform, which predictably generates customized molecules that harness the power of innate immune cells to eliminate tumor cells.  Several ICE^® molecules are currently in clinical development, being evaluated as single-agent or combination therapies. Headquartered in Mannheim, Germany, Affimed is led by a team of experienced biotechnology and pharmaceutical professionals united by a bold vision to prevent cancer from ever disrupting patients’ lives. For more information about the Company’s team, pipeline, and partners, please visit: .

Investor Relations Contact
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail:
Tel.: +1 (917) 436-8102